On-demand webinar: “Small modalities, deep impact”: VHH antibodies as complementary approaches for challenging therapeutic targets
This webinar was held in collaboration with AXXAM
About this webinar:
Since 2019, small antibodies known as VHHs have been growing rapidly in popularity for diverse therapeutic applications, thanks to a series of FDA approvals for drugs using this modality.
VHH antibodies have distinct advantages over traditional antibodies, in terms of stability, simplicity, large-scale production, and target reach.
A further reason for high levels of interest in this format is that these properties mean that VHHs can be used in infinitely creative ways, through payload targeting, intracellular applications, and building more complex, cutting-edge technologies like targeted protein degradation (TPD).
Much interest is growing in the potential use of VHH therapeutics against difficult molecular targets, such as GPCRs, as the molecular weight of a VHH and the length of the CDR regions allow them to penetrate the receptor core and access ligand binding pockets and orthosteric/allosteric sites easily.
What you will learn:
- What makes VHH antibodies different, and examples of creative therapeutic applications.
- Successful case studies from Isogenica’s VHH libraries
- Functional assay development on GPCRs at Axxam
About our partnership:
Our partnership with Axxam offers our clients the access to a broad portfolio of services to support their early-stage discovery of therapeutic antibodies, combining our VHH libraries with Axxam’s functional assay development and cutting-edge high-throughput screening platforms.
Want to know more?